The Year in Clinical Cardiac Electrophysiology  by Marcus, Gregory M. et al.
W
2
T
i
i
a
m
A
W
p
s
t
w
s
f
f
n
w
t
u
s
a
r
p
T
t
a
l
a
p
T
o
d
t
F
F
C
M
s
S
M
a
Journal of the American College of Cardiology Vol. 56, No. 8, 2010
© 2010 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
PYEAR IN CARDIOLOGY SERIES
The Year in Clinical Cardiac Electrophysiology
Gregory M. Marcus, MD, MAS,* Melvin M. Scheinman, MD,* Edmund Keung, MD†
San Francisco, California
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.05.017r
r
d
f
[
w
o
0
t
t
b
s
d
C
h
h
a
d
w
a
b
a
m
b
i
d
w
r
e
d
t
a
t
m
a
r
d
e
b
b
a
pe reviewed hundreds of papers published between April 1,
009, and March 31, 2010, in preparation for this review.
his year showed a “bumper crop” of excellent papers. Our
ntent was to include those papers that either yield new
nsights into disease mechanism or provide important ther-
peutic advances. We apologize for the required omission of
any excellent studies.
trial Fibrillation (AF)
arfarin remains the most efficacious therapy available to
revent stroke in the setting of AF (1–3). However, several
ubstantial limitations of the drug have motivated research
o develop superior alternatives. Perhaps most important,
arfarin is associated with an increased risk of hemorrhagic
troke. In addition, the food and drug interactions and need
or ongoing monitoring make the drug particularly difficult
or patients to take. This year, several studies examining
ew therapies for stroke prevention in the setting of AF
ere published.
The first study is the first published major trial of a direct
hrombin inhibitor since the SPORTIF (Stroke Prevention
sing an ORal Thrombin Inhibitor in atrial Fibrillation)
tudies examining ximelagatran. Although ximelagatran
ppeared to be similar to warfarin in efficacy and bleeding
isk, it resulted in hepatotoxicity (4). Connolly et al. (5)
ublished the RE-LY (Randomized Evaluation of Long-
erm Anticoagulation Therapy) study, a randomized trial
hat compared the blinded administration of 2 fixed doses of
new direct thrombin inhibitor, dabigatran, with open-
abeled use of warfarin in patients with AF and at least 1
dditional risk factor for stroke. A total of 18,113 AF
atients were enrolled, with median follow-up of 2.0 years.
he primary outcome of stroke or systemic embolism
ccurred in 182 patients receiving 110 mg twice daily of
abigatran (1.53% per year), 134 patients receiving 150 mg
wice daily of dabigatran (1.11% per year), and 199 patients
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ccepted May 25, 2010.eceiving warfarin (1.69% per year). Both doses of dabigat-
an were noninferior to warfarin (p  0.001). The higher
ose of dabigatran was also superior to warfarin (relative risk
or the primary end point: 0.66, 95% confidence interval
CI]: 0.53 to 0.82, p  0.001). Rates of hemorrhagic stroke
ere significantly smaller in those who received either dose
f dabigatran (relative risk: 0.31, 95% CI: 0.17 to 0.56, p 
.001 for the 110-mg dose; relative risk: 0.26, 95% CI: 0.14
o 0.49, p  0.001 for the 150-mg dose) compared with
hose who received warfarin. Major bleeding was similar
etween the 150-mg dose of dabigatran and warfarin, but
ignificantly less common in those on the 110-mg dose of
abigatran compared with warfarin (relative risk: 0.80, 95%
I: 0.69 to 0.93, p  0.003). There was a significantly
igher rate of major gastrointestinal bleeding with the
igher dose of dabigatran compared with warfarin. The only
dverse effect that was significantly more common with
abigatran compared with warfarin was dyspepsia. There
ere no significant differences in elevations of aspartate
minotransferase or alanine aminotransferase.
The RE-LY study therefore suggests that dabigatran may
e an acceptable alternative to warfarin in AF patients with
dditional risk factors for stroke. The higher dose may have
ore efficacy, with a risk of hemorrhagic stroke and major
leeding comparable to that of warfarin and risk of gastro-
ntestinal bleeding higher than that of warfarin. The lower
ose of the drug appears to have comparable efficacy to
arfarin, with evidence that there may be a lower bleeding
isk. Therefore, future research, clinical experience, and
xpert consensus may teach us how to best risk stratify to
etermine optimal dosing for individual patients. Impor-
antly, 80% of the active drug is excreted by the kidneys, and
creatinine clearance 30 ml was an exclusion criterion for
he trial. Therefore, patients with significant renal impair-
ent may not be candidates for this new therapy. In
ddition, to enhance absorption of dabigatran, a low pH is
equired. Therefore, the dabigatran capsules contain
abigatran-coated pellets with a tartaric acid core. This may
xplain the dyspepsia and higher rates of gastrointestinal
leeding with the higher dose. It also suggests that H2-
lockers and proton pump inhibitors might affect the
bsorption and potentially reduce the efficacy of the drug.
The second trial studying a novel approach to stroke
revention in AF was the PROTECT AF (WATCHMAN
eft Atrial Appendage System for Embolic Protection in
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trial investigating the WATCH-
MAN device (Atritech, Plymouth,
Minnesota) (6). This is a self-
expanding nickel titanium (niti-
nol) frame structure with fixation
barbs and a permeable polyester
fabric cover implanted via a trans-
septal approach to seal the left
atrial appendage (7). Based on
the findings that the left atrial
appendage is the source of thrombi
in more than 90% of patients with
AF and building on pilot studies
that showed acceptable risk-to-
benefit ratios for this approach
(8–10), PROTECT AF enrolled
707 AF patients with an addi-
tional risk factor for stroke ran-
domly assigned in a 2:1 ratio to
percutaneous closure of the left
atrial appendage or warfarin
therapy. The device was success-
fully implanted in 88% of those
assigned to the intervention. At
the pre-specified 45-day follow-
up, 86% of the device patients had
a transesophageal echocardiogram
that met the pre-defined criteria
necessary to discontinue warfarin.
After stopping warfarin, partici-
ants with the device were prescribed clopidogrel 75 mg
aily and aspirin 81 mg daily. The clopidogrel was stopped
fter the 6-month follow-up visit. After a mean follow-up of
8  10 months, the primary efficacy rate of stroke
including ischemic or hemorrhagic), cardiovascular or un-
xplained death, or systemic embolism was 3.0 per 100
atient-years (95% CI: 1.9 to 4.5) in the intervention group
nd 4.9 per 100 patient-years (95% CI: 2.8 to 7.1) in the
ontrol group. The probability of noninferiority to warfarin
as99.9% based on a 2-fold noninferiority margin. When
he analysis was restricted to only those in the intervention
roup who had successful device implantation allowing for
arfarin discontinuation, the device was found to be supe-
ior for this primary efficacy end point (rate ratio 0.40, 95%
I: 0.19 to 0.91). Ischemic strokes were more common in
he intervention group, and hemorrhagic strokes were more
ommon in the warfarin group. Complications of the device
mplant procedure included serious pericardial effusion in 22
4.8%), procedure-related ischemic stroke attributed to air
mbolism in 5 (1.1%; these events were counted toward the
otal ischemic strokes in the intervention arm), and device
mbolization in 3 (0.6%). There were no deaths deemed
elated to the closure device.
PROTECT AF provides good evidence that a percuta-
Abbreviations
and Acronyms
AF  atrial fibrillation
ARVC  arrhythmogenic
right ventricular
cardiomyopathy
CI  confidence interval
CRT  chronic
resynchronization therapy
HF  heart failure
HR  hazard ratio
ICD  implantable
cardioverter-defibrillator
LQTS  long QT syndrome
LVEF  left ventricular
ejection fraction
NOS1AP  nitrous oxide
synthetase adaptor protein
NYHA  New York Heart
Association
PF  Purkinje fibers
STEMI  ST-segment
elevation myocardial
infarction
VF  ventricular fibrillation
VT  ventricular
tachycardia
WPW  Wolff-Parkinson-
White syndromeeously placed left atrial appendage occlusion device might te a reasonable alternative to warfarin in patients with AF
nd additional stroke risk factors. The fact that those with
uccessful closure fared better than those assigned to war-
arin is proof of principle that the left atrial appendage is
ndeed likely the culprit in the majority of strokes due to
F. In interpreting the results of this important study, there
re several considerations that should be kept in mind.
everal important limitations of the study are described in
n accompanying editorial (11), including the evident sub-
tantial learning curve associated with device implantation,
he fact that approximately 10% of device patients who had
iscontinued warfarin restarted it for clinical reasons, the
nding of thrombus formation on the device in 15 patients
espite the prescribed warfarin and antiplatelet therapy, and
he wide CIs in the primary efficacy estimate that resulted
rom relatively small numbers. In addition, although the
roups were generally well balanced, patients in the control
warfarin) group more often had diabetes and permanent
F, but because no p values or CIs were provided for these
stimates, it is not clear whether these differences were
tatistically significant. In addition, the device could not be
uccessfully implanted in everyone, and even in those in
hom it was implanted, warfarin could not be stopped on
he basis of the pre-defined transesophageal echocardiogram
riteria in everyone. Finally, because all device patients
eceived warfarin until the device was well seated and the
ppendage sealed, this study does not address whether those
ith strict contraindications to warfarin should be consid-
red for left atrial appendage closure.
The ACTIVE A (Atrial Fibrillation Clopidogrel Trial
ith Irbesartan for Prevention of Vascular Events) study
ddressed an approach that is immediately available in
linical practice for those AF patients with additional stroke
isk factors that cannot take warfarin (12). Of note, the
CTIVE W trial previously showed that combination
spirin and clopidogrel was inferior to warfarin in stroke
revention in these patients (13). ACTIVE A enrolled
,554 AF patients with at least 1 additional risk factor for
troke who were felt to be unsuitable for warfarin therapy.
hey were randomized to clopidogrel at 75 mg/day versus
lacebo in a double-blind fashion. All patients also received
spirin at a recommended dose of 75 to 100 mg/day. The
rimary outcome of any major vascular event (stroke,
on-central nervous system embolism, myocardial infarc-
ion, or death from vascular causes) was 6.8% per year in the
lopidogrel group versus 7.6% per year in the placebo group
relative risk: 0.89, 95% CI: 0.81 to 0.98, p  0.01). This
enefit was primarily due to a decrease in stroke. Patients in
he clopidogrel group experienced major bleeding signifi-
antly more frequently than those in the placebo group
relative risk: 1.57, 95% CI: 1.29 to 1.92, p  0.001).
lthough both severe major bleeding and intracranial bleed-
ng were more common with clopidogrel, there were no
etectable differences in hemorrhagic stroke or fatal bleed-
ng. In sum, clopidogrel plus aspirin appears to be superior
o aspirin alone in preventing stroke in the setting of AF,
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August 17, 2010:667–76 Year in Electrophysiologyut at a cost of more bleeding. The benefit is somewhat
ncremental, but may be worthwhile in a patient deemed to
e unsuitable for warfarin if the appropriate counseling
egarding risks and benefits is performed.
The last alternative approach to stroke prevention in AF
omes from a secondary analysis of the ATHENA (A
lacebo-controlled, double-blind, parallel-arm Trial to as-
ess the efficacy of dronedarone 400 mg BID for the
revention of cardiovascular Hospitalization or death from
ny cause in patiENts with Atrial fibrillation/atrial flutter)
rial (14). Although it seems intuitive that maintenance of
ormal sinus rhythm in AF would lead to a reduction in
trokes, well-conducted prospective studies comparing
hythm control with rate control failed to demonstrate such
difference (15,16). Importantly, in these studies, vitamin K
ntagonists could be discontinued if there was evidence of
inus rhythm at follow-up in the rhythm control group. The
ajority of strokes occurred in those who either were not
ndergoing vitamin K antagonist therapy or in whom the
nternational normalized ratio was subtherapeutic. Because
F can often be asymptomatic (17), the supposition has
een that these patients thought to be in sinus rhythm were
n fact having episodes of undetected AF. The main results
f ATHENA were previously published (18). This analysis
xamined whether the 2,301 AF patients randomized to
ronedarone experienced fewer strokes than the 2,327 AF
atients randomized to placebo. All patients had at least 1
dditional risk factor for stroke, and both groups had a mean
HADS2 score of 2.0. Particularly important in inter-
reting this study is the fact that stroke outcomes were not
re-specified or centrally adjudicated. Instead, information
egarding stroke was gathered from hospitalization reports
nd death reports. Strokes that did not lead to hospitaliza-
ions or death were reported as adverse events. Approxi-
ately 60% of all participants were receiving vitamin K
ntagonist therapy at baseline, and this was well balanced
etween the groups.
In ATHENA, there were 70 strokes with placebo (1.8%
er year) compared with 46 strokes with dronedarone (1.2%
er year), yielding a hazard ratio (HR) of 0.66 (95% CI:
.46 to 0.96, p  0.027). The Kaplan-Meier curves were
oted to separate early and remain that way throughout the
tudy. The investigators did not report whether this reduc-
ion in stroke was mediated by a reduction in AF. Of note,
hose receiving dronedarone exhibited a trend toward lower
ystolic blood pressure and a significant reduction in dia-
tolic blood pressure compared with placebo, suggesting
hat the antihypertensive effect may have contributed to the
ower rate of stroke. Finally, unlike previous studies exam-
ning antiarrhythmic agents and stroke prevention, the
tandard of practice had changed by the time this trial was
onducted such that presence of sinus rhythm did not
ecessarily result in discontinuation of vitamin K antagonist
herapy. Therefore, it remains unknown whether a similar
ffect might have been observed with other antiarrhythmic prugs if continuation of vitamin K antagonists had been
niform between rhythm and rate control groups.
Moving from stroke prevention in AF to treatment of
ymptoms due to AF, Wilber et al. (19) reported the
hermoCool AF trial, a prospective, multicenter, random-
zed (2:1) trial comparing open irrigated catheter ablation
n  106) with antiarrhythmic drug therapy (n  61).
nrollment required at least 3 symptomatic AF episodes in
he last 6 months and failure to respond to at least 1
ntiarrhythmic drug. In addition to follow-up at intermit-
ent visits for symptoms of AF, all participants were
equired to transmit symptomatic episodes using trans-
elephonic monitoring. For the ablation procedure, pulmo-
ary vein isolation confirmed by entrance block was re-
uired, and additional lesion sets were allowed based on the
reating physician’s discretion. For those assigned to the drug
rm, the choice of drug was at the discretion of the investigator.
he majority in the drug arm received either flecainide or
ropafenone. A 3-month blanking period was in place after
atheter ablation in the ablation arm, and a 14-day blanking
eriod was in place during titration of medicines in the drug
rm, during which efficacy was not assessed. Although repeat
blation procedures were allowed, the primary results reflected
utcomes after a mean 1.1 procedures per patient. The primary
nd point of freedom from protocol-defined treatment failure,
hich included documented symptomatic paroxysmal AF
uring the 9-month effectiveness evaluation period, was 66% in
he catheter ablation group and 16% in the antiarrhythmic
rug group (HR: 0.30, 95% CI: 0.19 to 0.47, p  0.001).
here was also evidence based on serial SF-36 questionnaires
hat quality of life improved significantly in the ablation group
ompared with the antiarrhythmic drug group. Thirty-day
ajor treatment-related adverse events occurred in 5 patients
5%) in the ablation group (1 pericardial effusion, 1 pulmonary
dema, 1 pneumonia, 1 vascular complication, and 1 heart
ailure [HF]) and in 5 patients (9%) in the drug group (2
ife-threatening arrhythmias and 3 with drug intolerance re-
uiring discontinuation).
Although the ThermoCool AF trial appears to demon-
trate superior efficacy in preventing symptomatic recurrent
F in those who received catheter ablation compared with
hose who received antiarrhythmic drug therapy, there are a
ew caveats to bear in mind. First, although this is the most
igorous, multicenter catheter ablation trial done to date, the
enters involved were generally quite experienced in the
rocedure. The findings may therefore not apply to all
enters. Because all patients had failed at least 1 antiarrhyth-
ic drug and because the study was clearly not blinded,
hese presumably motivated patients might have subjectively
avored their symptomatic response to an involved, invasive
rocedure. However, the investigators were careful to in-
lude trans-telephonic monitoring as well as Holter studies,
ith good evidence that AF was in fact substantially less
ommon after ablation. In addition, those who failed drug
herapy may represent patients who are destined to do
oorly on drug treatment. The ongoing CABANA (Cath-
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trial Fibrillation Trial) compares ablation with drugs as
rimary therapy. Although the 3-month blanking period
fter ablation is reasonable, this did result in less follow-up
ime for those undergoing ablation. In addition, some
vidence suggests that, over time, late AF recurrence may
eturn. Therefore, this 9-month efficacy end point (and
ean follow-up of 12.5 months) may not be sufficient to
each us about long-term results.
Finally, a new risk factor for AF has recently emerged.
sing data from the Framingham Heart Study, investiga-
ors examined the PR interval in 7,575 individuals as a
redictor of incident AF, pacemaker implantation, and
ortality (20). Dichotomizing the PR interval into 200
s or not (i.e., first-degree heart block or not), they found
hat first-degree heart block was associated with an unad-
usted HR of 4.26 (95% CI: 2.85 to 6.38) for AF (absolute
ncrease, 1.04% per person-year), 10.26 (95% CI: 6.66 to
5.82) for pacemaker implantation, and 2.72 (95% CI: 2.11
o 3.51) for all-cause mortality. After multivariable adjust-
ent, an increasing PR interval was associated with an
ncreased risk for each of these outcomes. Similar results
ere observed after excluding individuals taking nodal-
locking medications. There was previously a perception
hat a first-degree AV block was benign (21–23), and this
ell-conducted study suggests this may not in fact be the
ase. Although there is currently no clear therapeutic option
hat would necessarily change the management for an
ndividual found to have first-degree AV block, and al-
hough the number needed to harm for AF was 96 (i.e.,
ost individuals with first-degree AV block will not develop
F), these findings may help identify patients at risk for AF
n combination with other risk factors (24) and may help
eveal mechanisms responsible for the disease. In fact, there
re several potential mechanisms that might be responsible:
longer PR interval may be due to atrial fibrosis and
ecreased atrial conduction time. Or, it might reflect general
brosis, affecting both the conduction system and the atria.
t may also reflect greater vagal tone, which might also be
esponsible for AF. Finally, the long PR might itself have
emodynamic consequences that lead to AF.
entricular Arrhythmias
he meaning of sustained ventricular tachycardia (VT) or
entricular fibrillation (VF) in the setting of a high-risk
T-segment elevation myocardial infarction (STEMI) was
tudied as a secondary analysis of the APEX AMI (Assess-
ent of Pexelizumab in Acute Myocardial Infarction) trial
25). Of 5,745 acute STEMI patients felt to be high risk
mainly excluding isolated inferior wall STEMI), sustained
T/VF occurred in 329 (5.7%). Twenty-five patients had
he arrhythmia before cardiac catheterization, 180 had it
uring the cardiac catheterization procedure, and 117 had
he event after the procedure. Ninety percent occurred
ithin 48 h. Those receiving beta-blockers, angiotensin- honverting enzyme inhibitors or angiotensin receptor block-
rs, or statins had VT/VF less often, and those on class I
nd III antiarrhythmic drugs, receiving an intra-aortic
alloon pump, undergoing repeat cardiac catheterization,
ndergoing dialysis, or requiring a blood transfusion more
ften had VT/VF. Important predictors of either early
before completion of the cardiac catheterization) or late
after the procedure) VT/VF were higher baseline heart
ate, lower systolic blood pressure, higher baseline ST-
egment deviation, and lower pre-procedural Thrombolysis
n Myocardial Infarction (TIMI) flow grade. Higher Killip
lass, inferior myocardial infarction, lower creatinine clear-
nce, shorter time from symptom onset to randomization,
nd higher weight were associated with early VT/VF.
ost-procedural TIMI flow grade 3, lack of beta-blockers
n admission, and ST-segment resolution 70% were
ssociated with late VT/VF. Mortality in those with any
T/VF was significantly higher than those without it
23.2% vs. 3.6%, HR: 7.33, 95% CI: 5.61 to 9.59). The
xcess mortality was mainly confined to the first 30 days and
as more common in those with late VT/VF. After adjust-
ent for potential confounders, VT/VF remained associ-
ted with a significant increase in mortality. Of note, 70
91%) of the deaths occurring in the VT/VF patients were
ardiovascular, and of these, 30 (43%) were due to sudden
ardiac death. Of interest, a similar proportion of those with
o VT/VF had sudden death (36%, p  0.67). Therefore,
he mechanism of death may be related to the generally
icker hearts and/or the conditions associated with more
T/VF. It remains unknown whether the ventricular ar-
hythmia is causally related to worse outcomes or whether it
imply reflects worse heart disease.
Recently, early repolarization or J-point elevation in the
nferior and lateral leads has been shown to be more
ommon in patients with idiopathic VF compared with
ontrols (26,27). Although the association appears to be
uite strong, the risk of an adverse event when confronted
ith an asymptomatic patient with early repolarization
emained unknown. Investigators in Finland examined the
aseline electrocardiograms (ECGs) in 10,864 subjects in
he Social Insurance Institution’s Coronary Heart Disease
tudy that were obtained between 1966 and 1972 (28).
arly-repolarization patterns were sought in the inferior and
ateral leads and stratified according to the degree of J-point
levation (0.1 or 0.2 mV) that was either notched or
lurred in 2 consecutive leads. The cause of death was
etermined by examining death certificates. All deaths from
cardiac cause were then reviewed, including review of
ospital records, to determine whether the death was likely
ssociated with an arrhythmia or not. J-point elevation of at
east 0.1 mV was present in 630 (5.8%) of participants at
aseline. Those with inferior lead J-point elevation were
ore often male, smokers, had a lower resting heart rate, a
ower body mass index, lower blood pressure, a shorter QTc
nterval, a longer QRS duration, and were more likely to
ave ECG evidence of coronary artery disease. Those with
l
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August 17, 2010:667–76 Year in Electrophysiologyateral J-point elevation were more likely to have left
entricular hypertrophy. During follow-up of 30 11 years,
13 (56.5%) patients died. Of these deaths, 1,969 (32%)
ere due to cardiac causes, and of those, 795 (40%) were
udden. Before and after multivariable adjustment, subjects
ith J-point elevation of at least 0.1 mV in the inferior leads
n  384) had a higher risk of cardiac death (adjusted
elative risk: 1.28, 95% CI: 1.04 to 1.59, p  0.03) and
rrhythmic death (adjusted relative risk: 1.43, 95% CI: 1.06
o 1.94, p  0.03). However, these patients did not have a
ignificantly higher rate of all-cause mortality. Before and
fter multivariable adjustment, subjects with J-point eleva-
ion of 0.2 mV (n  36) had an increased risk of cardiac
eath (adjusted relative risk: 2.98, 95% CI: 1.85 to 4.92, p
.03), arrhythmic death (adjusted relative risk: 3.94, 95%
I: 1.96 to 7.90, p  0.03), and death from any cause
adjusted relative risk: 1.54, 95% CI: 1.06 to 2.24, p 
.03). Although J-point elevation in the lateral leads was
ssociated with arrhythmic death, it predicted cardiac and
ll-cause death with borderline significance. Early repolar-
zation appears to be associated with worse cardiovascular
utcomes, but the exact mechanism remains to be eluci-
ated. The mechanism may also differ between patients.
lthough the event rates were relatively high, particularly in
hose with J-point elevation 2.0 mV, the follow-up was
uite long. Additional research is needed to narrow down
he particular patients at highest risk and to inform us about
creening strategies and ultimately preventive therapies. It
oes appear that inferior lead J-point elevation and partic-
larly prominent J-point elevation may be important risk
actors.
Although an implantable cardioverter-defibrillator (ICD)
s an effective tool for secondary prevention in individuals
ho have suffered a cardiac arrest without a reversible cause
29,30), determining the etiology of the event remains
mportant. Although coronary artery disease and systolic
ysfunction represent the most common precipitants, car-
iac arrest survivors without evident cardiac disease remain
challenge to diagnose. Determining the cause can help
uide adjuvant therapy (potentially helping to reduce palpi-
ations, syncope, and ICD shocks), can help inform appro-
riate patient counseling regarding activity and particular
rugs to avoid, and can help determine whether family
creening is beneficial. Krahn et al. (31) performed a
rospective study in 9 centers across Canada wherein
atients with unexplained cardiac arrest and no evident
ardiac disease underwent systematic evaluation including
ardiac magnetic resonance imaging (MRI), signal-averaged
CG, exercise testing, drug challenge (including intrave-
ous epinephrine and procainamide challenges), and selec-
ive invasive electrophysiological testing and/or endomyo-
ardial biopsy. Early repolarization was defined as J-point
levation of at least 0.1 mV in at least 2 inferior or lateral
eads. Over approximately 4 years, 63 patients with unex-
lained cardiac arrest were identified. All had an ejection
raction 50% and normal coronary arteries. None had ivert evidence of a prolonged QT interval, arrhythmogenic
ight ventricular cardiomyopathy (ARVC), the Brugada
yndrome, ST-segment elevation, evidence of hypertrophic
ardiomyopathy on imaging, anomalous coronary arteries,
ad experienced commotio cordis, or had a regular wide
omplex tachycardia consistent with idiopathic VT. With
he systematic testing, 35 patients (56%) received a specific
iagnosis: long QT syndrome (LQTS) was diagnosed in 8
23%), catecholaminergic polymorphic VT was diagnosed
n 8 (23%), ARVC in 6 (17%), early repolarization in 5
14%), coronary spasm in 4 (11%), Brugada syndrome in 3
9%), and myocarditis in 1 (3%). Provocative testing had the
ighest yield of all the different components, with abnormal
ndings in 18 patients (29%). Subsequent targeted genetic
esting was performed in 19 patients, and evidence of a
ausative mutation was found in 9 (47%) of these. Family
creening of 64 family members of the 9 patients with
ausative mutations resulted in the discovery of mutations in
5 (24%), including 2 with LQTS, 4 with Brugada syn-
rome, and 9 with catecholaminergic polymorphic VT.
lthough the minority of those with resuscitated sudden
eath have no explanation, those somewhat rare patients are
ften young and otherwise healthy. In addition, that event
ay serve as a marker of risk in additional family members.
his important paper provides a useful algorithm that can
erve as a guide in evaluating these patients, potentially
elping to guide the most appropriate therapy and focused
enetic testing.
asic and Translational Studies
QTS. A wide array of important recent basic and trans-
ational observations bearing on clinical manifestations of
isease processes have been described. This is especially true
or the channels involved in the LQTS. Kapa et al. (32)
escribed the results of an in-depth analysis of the types,
requency, and site of mutation for the 3 genes most
ssociated with the LQTS, namely LQT1 (KCNQ1),
QT2 (KCNH2), and LQT3 (SCN5A). They compared the
enetic structure of 388 “definite” LQTS cases with 1,300
ealthy controls. Simple missense mutations (single amino
cid substitutions) were found to be most common in
QTS cases as well as controls. They found, however, that
imple missense mutation involving transmembrane, linker,
r pore regions of KCNQ1 or KCNH2 were far more likely
o correlate with disease state. In contrast, nonmissense
utations (i.e., frameshift, deletions, and so on) usually
esulting in radical changes in channel structure were almost
lways associated with disease.
The discussion section of this work is especially helpful in
mphasizing the clinical role of genetic resting. Such testing
annot be totally expected to result in a yes/no affirmation of
isease in view of the “background” noise of rare missense
utations in the normal population. This study is verymportant in highlighting the correlation of both the type
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isease.
Another potentially important contribution to our under-
tanding of the causes of variations in penetrance in the
QTS is provided by a study by Crotti et al. (33). The
uthors studied a homogenous type of KCNQ1 (A341V)
egregating a founder (CK) mutation in South African
amilies. They were able to study 500 subjects, 205 of whom
ere mutation carriers. The cohort was divided into those
ith severe symptoms (aborted sudden death or sudden
eath) compared with those with syncope.
The authors correlated both symptom severity as well as
T-interval duration with genetic variations in nitrous
xide synthetase adaptor protein (NOS1AP). This was
hosen because prior studies in several large population
tudies showed that NOS1AP was associated with small
uantitative increases in the QT interval (34,35). In addi-
ion, this same gene has been associated with increased risk
f death in a general population (36). The authors found a
ignificant association with presence of symptoms and
ymptom severity, as well as greater likelihood of manifest-
ng a QT interval, in the top 40% of mutation carriers.
Although the physiological link between NOS1AP and
ffects on the LQTS are speculative (37), nevertheless, the
uthors present impressive evidence for the role of
OS1AP as a genetic modifier in phenotypic expression
f symptoms in a very homogenous LQTS population. This
tudy breaks new ground in potentially explaining symptom
everity in a specific LQTS population, and no doubt future
tudies will assess association of NOS1AP with other known
enetic arrhythmia syndromes.
The adverse effects of hypokalemia in patients with either
ongenital or drug-induced LQTS are well established. The
recise mechanism of these adverse effects is not clear. An
mportant study by Guo et al. (38) addressed this issue using
uman embryonic kidney cells as well as in vivo rabbit
tudies. In a very detailed and meticulous study, they found
hat the rapid potassium delayed rectifier current membrane
ensity of the IKr channel (KCNH2 gene) is controlled by
he external K concentration. They showed that lowering
he K concentration rapidly (overnight incubation in zero
 concentration) accelerated the internalization and deg-
adation of the IKr channels. This occurred in a K

oncentration-dependent fashion. However, hypokalemia
roduced no significant changes in Kv1.5 (Kur) and a
odest reduction (30.3%) in KvLQT1 (IKs) current.
Further observations included studies of rabbits fed low K
ompared with those fed identical diets with K. The hypo-
alemia rabbits showed a prolongation of both the QTc as well
s action potential duration. They found that IKr expression
as much lower in the hypokalemia group, but there was no
ignificant changes in the L-type calcium current, inward
ectifier current IKr, or the slow delayed rectifier current (Iks).
hese unique observations demonstrate the critical role of
ypokalemia in the regulation of the cell surface density of an ton channel and have important implications in the role of
ypokalemia on the genesis of torsades.
RVC. An important study evaluating the structure and
unctional link between plakophilin-2 (PKP2) and sodium
hannel function is described by Sato et al. (39). Myocardial
ells are joined by a specialized structure known as the
ntercalated disc. This region comprises proteins that pro-
ide mechanical support (desmosomes and adherens junc-
ions) as well as gap junctions that allow for both metabolic
nd electrical connection between myocytes. PKP2 is a
omponent of the desmosomes, and mutations in PKP2
ave been linked to the clinical entity of ARVC.
The authors used monolayers of neonatal rat myocytes
nd observed coprecipitation of the alpha subunit of the
odium channel (Nav 1.5) with PKP2. They showed that
oss of expression of PKP2 had profound effects on the Na
urrent in that both peak current Na was diminished as
ell as delayed recovery from inactivation. Both of these
ndings led to substantial decreases in Na current and
onduction velocity. Importantly, they showed for the first
ime that loss of PKP2 expression led to conduction block
nd re-entrant arrhythmias.
Previous studies have shown that loss of PKP2 expression
s associated with decreased connexin expression and cell-
o-cell coupling (40). More recently, Asimaki et al. (41)
emonstrated the high sensitivity and specificity of de-
reased plakoglobin staining for the diagnosis of ARVC.
he current study further emphasizes the important link
etween intact desmosomal development and properties of
ell-to-cell conduction and their role in the genesis of
ardiac rhythm disorders (39).
F. Observations related to ion-channel subunit expres-
ion in Purkinje fibers (PFs) in congestive HF were reported
y Maguy et al. (42). Recent basic and clinical observations
ighlighted the role of PFs in the genesis of cardiac
rrhythmias, both in patients with and without structural
ardiac disease (43,44).
In this study, the authors set out to define changes in
ubunit mRNA and protein expression of ion channels
nd connexin in a dog model of congestive HF induced by
apid ventricular pacing. The major findings were down-
egulation of proteins involved in conduction, namely the
a channel Nav1.5 (56%), connexin (Cx)40 (66%), and
x43 (56%). They found decreased distribution of both
x40 and Cx43 in the central intercalated disc region.
Electrophysiological studies showed no significant
hanges in the resting membrane potential or in action
otential duration, but significant decreases in action po-
ential amplitude as well as overshoot and phase zero
pstroke in the PFs from the HF dogs. The His-Purkinje
onduction velocity decreased, as manifested by a 39%
ncrease in the H-V interval. These observations add further
nsight into the possible mechanisms of sudden cardiac
eath in the failing heart.
he Wolff-Parkinson-White (WPW) syndrome. An in-riguing paper by Lalani et al. (45) describes a new genetic
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August 17, 2010:667–76 Year in Electrophysiologybnormality associated with WPW patterns and musculo-
keletal and neurocognitive defects. To date, although
amilial clustering of the WPW syndrome has been de-
cribed, only 1 gene (PRKAG2) has been identified as being
ssociated with WPW (46). The latter is due to distortion of
he atrioventricular annulus by glycogen-filled myocytes that
rings atrium and ventricle in continuity.
The syndrome described by Lalani et al. (45) involves a
icrodeletion of 20p12.3, with all patients showing involve-
ent of a single gene (BMP2). Bone morphogenetic protein
elongs to the class of proteins that includes transforming
rowth factor and is involved in the development of the
trioventricular canal. Selective deletion of proteins in this
amily has been shown to produce pre-excitation in mice
47). These observations point to the finding of only the
econd gene implicated in the WPW pattern.
mplantable Devices
ardiac resynchronization therapy (CRT) and ICD. The
ADIT-CRT (Multicenter Automatic Defibrillator Im-
lantation Trial-Cardiac Resynchronization Therapy) trial,
ponsored by Boston Scientific, is a pivotal trial that may
otentially expand the use of CRT devices in HF manage-
ent. At the end of 2.4 years, when compared with an ICD
lone, the use of a CRT device that includes defibrillation
CRT-D) significantly reduced all-cause mortality or HF
vents (primary composite end point) by 34% in asymptom-
tic or mild symptomatic (New York Heart Association
NYHA] functional class I and II for ischemic and class II
or nonischemic dilated cardiomyopathy) patients with a left
entricular ejection fraction (LVEF) 30% and a QRS
uration of 130 ms (48). These numbers would argue for an
xpanded indication for CRT-D to include the estimated
illions of asymptomatic or mildly symptomatic patients
ith significantly reduced LVEF. However, further exam-
nation of the data raises the question of whether the risks
f implanting a CRT-D device in patients with mild HF are
orth the benefit in a wider patient population on the open
arket. There was no difference in mortality (3% annually);
he effectiveness was driven by a 41% reduction in HF
vents (primarily in hospitalization rate) among patients
ith a QRS duration 150 ms and left bundle-branch
lock. CRT-D therapy was associated with more system-
elated complications. As a result, the proportion of patients
xperiencing complications from any cause (system-related
nd HF events) at any time was similar (60.4% in the
RT-D and 59.7% in the ICD group). Another question is
hether the study patients were truly as healthy as typical
eal-world functional class I or II patients because 40% were
reviously hospitalized for HF and 10% were in NYHA
unctional class III or IV more than 3 months before
nrollment. Even under these conditions, the study failed to
how that NYHA functional class I patients benefited from
RT-D. Furthermore, this group of patients is more likelyo have a very active lifestyle than class III or IV patients. ievice complications are possibly higher, and living with a
RT-D may have a bigger negative impact on their quality
f life and, consequently, on patient acceptance. The long-
erm impact on cardiac performance and mortality from
hocks, appropriate or inappropriate, has yet to be ascertained.
fter considering some of these issues, the Circulatory System
evices Panel of the U.S. Food and Drug Administration
ecommended approval of CRT-D therapy to patients who
et the MADIT-CRT enrollment criteria with an added
equirement that these patients also have a left bundle-branch
lock.
isk prediction for sudden cardiac death. The SCD-
eFT (Sudden Cardiac Death in Heart Failure Trial) data
ere reanalyzed using a previously established risk-
redication model for HF (Seattle Heart Failure Model)
49). Patients were grouped into 5 quintiles of increasing
nnual mortality according to a set of clinical variables (age,
ex, systolic blood pressure, ischemic etiology, LVEF,
YHA functional class, serum sodium and creatinine, and
F medications). The benefits of ICD therapy on all-cause
ortality were related to the predicted risk quintile: the
owest risk quintile had a relative risk reduction of 54%,
ecreasing to 31% in the fourth quintile and zero in the
ighest risk quintile (predicted annual mortality 20%).
he effect was driven by lack of an effect of ICD therapy on
udden cardiac death in the highest risk quintile. The
nalysis reconfirmed that comorbidities reduce the survival
enefit of ICD therapy. The mode of death was analyzed in
he SCD-HeFT patients in another study (50). ICD
herapy had no effect on HF mortality. The reduction in
verall mortality with ICD therapy was due exclusively to a
eduction of sudden cardiac death, presumably due to ventric-
lar tachyarrhythmia. This finding was similar to that in the
ADIT-II analysis. Remarkably, there was no benefit of ICD
herapy in reducing ventricular tachyarrhythmia death in
YHA functional class III patients, who were more likely to
ie from HF. However, in the absence of more data, the result
f this subgroup analysis should not lead to exclusion of ICD
herapy in NYHA functional class III patients.
nternal defibrillator implantation. The relationship be-
ween physician credentials and ICD implantation were
valuated using data from the American College of
ardiology-National Cardiovascular Data Registry (51).
hen compared with board-certified electrophysiologists,
he incidence of ICD insertion complications was statisti-
ally higher among nonelectrophysiologist cardiologists
3.5% vs. 4.0%; relative risk: 1.11; 95% CI: 1.01 to 1.21).
he vast majority of the implants were performed by
lectrophysiologists (71%), and nonelectrophysiologists
ere less likely to implant a CRT-D in eligible patients.
embers of the electrophysiology community have long
rgued against nonelectrophysiologists implanting ICDs.
ut before electrophysiologists use the result as a mandate
f exclusion, it is important to point out that the higher
omplication rate occurred only in dual-chamber ICD
mplantations. Remarkably, adding an atrial lead increased
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Year in Electrophysiology August 17, 2010:667–76omplication rates for both electrophysiologists and non-
lectrophysiologists (2.1% and 3.1%, respectively, for single-
nd dual-chamber ICDs among electrophysiologists; 2.5%
nd 3.7%, respectively, among nonelectrophysiologists). But
he absolute dual-chamber ICD complication rate for non-
lectrophysiologists reached statistical significance when
ompared with electrophysiologists. Based on this analysis,
n argument can be made for nonelectrophysiologists to
imit their implantations to single-chamber ICDs. Because
he majority of the implantations are for primary prevention
83% in this study), which requires a single-lead device as
andated by Centers for Medicare and Medicaid Services,
onelectrophysiologists can continue their role in improving
ccess to ICD therapy. As pointed out in the accompanying
ditorial, factors other than skill sets and training may be
nvolved in a lower CRT-D implant rate by nonelectro-
hysiologist cardiologists (52). One can argue that they are
n a better position to consider confounding clinical factors
hat may lead to a decision not to implant a CRT-D.
acing. The PACE (Pacing to Avoid Cardiac Enlarge-
ent) study revisited the superiority of biventricular pacing
ver right ventricular pacing (53). After 12 months of
ontinuous pacing in patients with normal systolic function,
ight ventricular apical pacing reduced LVEF by 6.7 abso-
ute percentage points (from 61.5  6.6% to 54.8  9.1%)
nd increased left ventricular end-systolic volume by 25%
from 28.6  10.7 ml to 35.7  16.3 ml), whereas
iventricular pacing effected no changes. The number of
atients in this study was small and the follow-up period
as short, and more importantly, the reduction in the values
f the selected end point parameters was not associated with
ny significant clinical differences. Taking into consider-
tion the much higher complication rate associated with
iventricular system implantation (not reported in the pa-
er) and more frequent and higher cost of generator
eplacements due to high left ventricular output demand on
he battery, this study did not offer any compelling reason
or biventricular pacing at the time of implantation for all
atients with normal ventricular function.
Despite the obvious evidence of the deleterious effects of
ight ventricular pacing in ICD patients with left ventricular
ystolic dysfunction in the DAVID (Dual Chamber and
VI Implantable Defibrillator) trial, the DAVID II trial
as launched to confirm that the culprit was really “exces-
ive” right ventricular pacing only (54). Accordingly, AAI
acing mode at a relatively high pacing rate of 70 beats/min
as compared with VVI pacing at 40 beats/min. There were
o significant differences in the combined end point of time
o death or HF hospitalization between these 2 pacing
odes during a mean follow-up of 2.7 years. The incidence
f AF, syncope, shocks, and quality of life also did not show
ny differences. The findings are not surprising in view of
he results of the DAVID trial. The issue is obviously not
ual-chamber versus single-chamber ICD; it is a question of
excessive” RV pacing. The algorithm for programming can
e surprisingly fundamental: avoid pacing if possible; ifacing is clinically required, use AAIR pacing (optimized to
atients’ physiological need) if possible.
anagement of device infection. The American Heart
ssociation updated its clinical guideline on cardiovascular
mplantable electronic device infections and their manage-
ent (55). The statement reported an increase in incidence
f infection out of proportion to increased rates of new
evice implantation. Risk factors include diabetes mellitus,
F, generator replacement and renal insufficiency, oral
nticoagulant and long-term corticosteroid use, presence of
ore than 2 pacing leads, fever within 24 h before implant,
emporary pacing, and early reintervention. Complete re-
oval of the device system is required to eradicate infection.
erioperative antimicrobial prophylaxis is the most effective
ay to lower infection. It also emphasizes that antibiotics
rophylaxis for routine dental, gastrointestinal, and genito-
rinary procedures is not indicated in patients with these
evices. Sonication of devices before culture allowed a group
f investigators to show that bacteria colonize cardiac
mplantable electronic devices without clinical signs of
nfection (56). However, the clinical implication is un-
nown. Data collected from a single center showed that
ercutaneous lead extraction can be safely performed with-
ut thoracotomy in patients with right-sided infectious
ndocarditis with intracardiac vegetations (valvular and
ead) by a team of very experienced operators (57).
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ox 1354, San Francisco, California 94143. E-mail: marcusg@
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